|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0026764,
umls-concept:C0030705,
umls-concept:C0043603,
umls-concept:C0205485,
umls-concept:C0542341,
umls-concept:C1257890,
umls-concept:C1280500,
umls-concept:C1518321,
umls-concept:C2587213,
umls-concept:C2603343
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-11
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skeletal events in patients with multiple myeloma. However, because of toxicity associated with long-term bisphosphonate treatment, establishing the lowest effective dose is important. This study compared the effect of two doses of pamidronate on health-related quality of life and skeletal morbidity in patients with newly diagnosed multiple myeloma.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:AbildgaardNielsN,
pubmed-author:AhlbergLuciaL,
pubmed-author:AndersenNiels FrostNF,
pubmed-author:CarlsonKristinaK,
pubmed-author:DahlInger Marie SIM,
pubmed-author:FayersPeterP,
pubmed-author:GimsingPeterP,
pubmed-author:GluudChristianC,
pubmed-author:GregersenHenrikH,
pubmed-author:Hjorth-HansenHenrikH,
pubmed-author:HjorthMartinM,
pubmed-author:JuliussonGunnarG,
pubmed-author:KnudsenLene MeldgaardLM,
pubmed-author:LinderOlleO,
pubmed-author:MylinAnneA,
pubmed-author:NesthusIngeridI,
pubmed-author:NielsenJohan LanngJL,
pubmed-author:TuressonIngemarI,
pubmed-author:VangstedAnnetteA,
pubmed-author:WaageAndersA,
pubmed-author:WestinJanJ,
pubmed-author:WisløffFinnF
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
973-82
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20863761-Aged,
pubmed-meshheading:20863761-Aged, 80 and over,
pubmed-meshheading:20863761-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20863761-Bone Density Conservation Agents,
pubmed-meshheading:20863761-Bone Diseases,
pubmed-meshheading:20863761-Diphosphonates,
pubmed-meshheading:20863761-Double-Blind Method,
pubmed-meshheading:20863761-Female,
pubmed-meshheading:20863761-Humans,
pubmed-meshheading:20863761-Infusions, Intravenous,
pubmed-meshheading:20863761-Jaw Diseases,
pubmed-meshheading:20863761-Kaplan-Meier Estimate,
pubmed-meshheading:20863761-Male,
pubmed-meshheading:20863761-Middle Aged,
pubmed-meshheading:20863761-Multiple Myeloma,
pubmed-meshheading:20863761-Osteonecrosis,
pubmed-meshheading:20863761-Proportional Hazards Models,
pubmed-meshheading:20863761-Quality of Life,
pubmed-meshheading:20863761-Risk Assessment,
pubmed-meshheading:20863761-Risk Factors,
pubmed-meshheading:20863761-Scandinavia,
pubmed-meshheading:20863761-Stem Cell Transplantation,
pubmed-meshheading:20863761-Time Factors,
pubmed-meshheading:20863761-Transplantation, Autologous,
pubmed-meshheading:20863761-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
|
|
pubmed:affiliation |
Department of Haematology, Rigshospitalet and Copenhagen University, Copenhagen, Denmark. peter.gimsing@rh.regionH.dk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
